Occhipinti, M.; Brambilla, M.; Galli, G.; Manglaviti, S.; Giammaruco, M.; Prelaj, A.; Ferrara, R.; De Toma, A.; Proto, C.; Beninato, T.;
et al. Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. J. Pers. Med. 2021, 11, 424.
https://doi.org/10.3390/jpm11050424
AMA Style
Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, Beninato T,
et al. Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 2021; 11(5):424.
https://doi.org/10.3390/jpm11050424
Chicago/Turabian Style
Occhipinti, Mario, Marta Brambilla, Giulia Galli, Sara Manglaviti, Maristella Giammaruco, Arsela Prelaj, Roberto Ferrara, Alessandro De Toma, Claudia Proto, Teresa Beninato,
and et al. 2021. "Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors" Journal of Personalized Medicine 11, no. 5: 424.
https://doi.org/10.3390/jpm11050424
APA Style
Occhipinti, M., Brambilla, M., Galli, G., Manglaviti, S., Giammaruco, M., Prelaj, A., Ferrara, R., De Toma, A., Proto, C., Beninato, T., Zattarin, E., Lo Russo, G., Gelibter, A. J., Simmaco, M., Preissner, R., Garassino, M. C., De Braud, F., & Marchetti, P.
(2021). Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine, 11(5), 424.
https://doi.org/10.3390/jpm11050424
